Myocardial infarction rapid detection kit and preparation method thereof

Abstract

The invention discloses a myocardial infarction triple rapid detection kit and a preparation method for the myocardial infarction triple rapid detection kit. The kit is formed by taking novel heart markers, that is, human myeloperoxidase (MPO) and heart fatty acid binding protein (FABP3) as basis, and matching with any of myocardial infarction markers CRP (C reactive protein), cTnI and Lp-PLA2. The kit is characterized by being capable of warning myocardial infarction diseases much earlier compared with the existing gold-label kit, and capable of warning the risk of the whole process before and after the occurrence of myocardial infarction. The kit is composed of a test paper card and a colour comparison card or a colloidal gold quantitative reading meter, wherein an anti-MPO specific antibody, an anti-FABP3 specific antibody and a colloidal gold pad resisting to any of other myocardial infarction markers are labelled on the test paper card simultaneously; and novel myocardial infarction markers are detected simultaneously by a colloidal gold immunochromatography technology at the first time, and the kit has the characteristics of being capable of realizing early warning and whole-course monitoring, simple and convenient to operate, rapid, suitable for field detection, economical and practical, and the like.

Description

technical field [0001] The invention relates to a rapid detection kit for myocardial infarction and a preparation method thereof. Background technique [0002] Acute myocardial infarction (AMI) is a serious threat to human health and is one of the major diseases that cause death and disability worldwide. Rapid diagnosis of early acute myocardial infarction and timely treatment are the keys to reducing patient mortality. For patients with myocardial infarction without typical chest pain and insignificant ECG changes, it is difficult to accurately diagnose only by ECG, echocardiography, and cardiac MRI. Therefore, the detection of serum myocardial markers is a necessary basis for the diagnosis of AMI. [0003] Myocardial markers refer to a series of biochemical substances that can be measured in the blood. They are specific to the myocardium. When the myocardial tissue is damaged, they can be released into the circulating blood in large quantities. By detecting changes in blo...

AI Technical Summary

Problems solved by technology

[0009] At present, most of the triple detection kits used in clinical practice mainly detect myoglobin, creatine kinase MB isoenzyme and troponin, and the defects of these detection reagents are: 1. The diagnosis time is late, and early warning cannot be given; 2. .Low diagnostic accuracy; 3. Low sensitivity; 4. Poor specificity

The increase of troponin and CK-MB levels occurs 4 hours after myocardial infarction, which cannot provide early warning of AMI. Although the release time of myoglobin into the blood is about 2 hours earlier than the former, the cardiac specificity is poor. Elevations can also occur in the setting of renal or skeletal muscle injury

The lack of sensitivity and specificity of the three items of AMI in clinical use caused a certain number of AMI missed patients

The old detection reagent can only show that myocardial infarction has occurred, but cannot warn of myocardial infarction

[0010] Although the electrocardiogram can also reflect the patient's condition, among the patients who have just developed chest pain, although some have already started the process of acute myocardial infarction, more than half of the electrocardiograms are normal, resulting in many patients dying due to delay in treatment

[0011] Looking at the existing products and literature reports, the detection of the old three items of myocardial infarction lags behind and has low accuracy; or the existing technology and product form of MPO, FABP3, and cTnI detect a single indicator, which cannot comprehensively and specifically warn myocardial infarction occurrence and development

Since MPO, FABP3, and cTnI are currently used clinically in different product forms, the production principles and operating procedures are different, and the compatibility is relatively poor. It is difficult to detect the three indicators simultaneously and quickly in a short period of time, which greatly affects A reasonable and comprehensive judgment of the risk of myocardial infarction in patients with acute ACS

Images